Completed PHASE3 INTERVENTIONAL NCT00004376

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

Sponsor: National Center for Research Resources (NCRR)

Interventions guanfacine

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Sep 30, 1994 Completion: Jun 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00004376, this PHASE3 trial focuses on Tourette Syndrome and remains completed. Sponsored by National Center for Research Resources (NCRR), it has been updated 5 times since 1994, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center for Research Resources (NCRR)
Yale University

Data source: Office of Rare Diseases (ORD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.